Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.240 +0.040 (+3.33%)

Official Closing Price Updated: 8:00 PM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	621,820
Open	1.240
Bid (Size)	1.240 (200)
Ask (Size)	1.310 (2,500)
Prev. Close	1.200
Today's Range	1.230 - 1.300
52wk Range	0.8700 - 3.190
Shares Outstanding	37,032,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What's going on in today's session ↗

March 03, 2026

Via Chartmill

These stocks are moving in today's session ↗

March 03, 2026

Via Chartmill

Performance

YTD	-22.5%	-22.5%
1 Month	-16.8%	-16.8%
3 Month	-23.9%	-23.9%
6 Month	-31.5%	-31.5%
1 Year	-13.9%	-13.9%

More News

Which stocks are gapping on Tuesday? ↗

March 03, 2026

Via Chartmill

Which stocks are moving before the opening bell on Tuesday? ↗

March 03, 2026

Via Chartmill

Which stocks are gapping on Monday? ↗

December 01, 2025

Via Chartmill

Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy

October 07, 2025

Via BreakingCrypto

Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

October 06, 2025

Via FinancialNewsMedia

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

July 28, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy

July 17, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

July 09, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

July 01, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

June 24, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗

June 18, 2025

Via Stocktwits

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

June 18, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology to Present at BIO International Convention 2025

June 10, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗

June 05, 2025

Via Benzinga

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

June 05, 2025

From MAIA Biotechnology

Via Business Wire

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

June 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000

May 27, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 15, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement

May 14, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement

May 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology Announces $1.08 Million Private Placement

May 05, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

April 01, 2025

From MAIA Biotechnology, Inc.

Via Business Wire

Frequently Asked Questions

Is MAIA Biotechnology, Inc. Common Stock publicly traded?

Yes, MAIA Biotechnology, Inc. Common Stock is publicly traded.

What exchange does MAIA Biotechnology, Inc. Common Stock trade on?

MAIA Biotechnology, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for MAIA Biotechnology, Inc. Common Stock?

The ticker symbol for MAIA Biotechnology, Inc. Common Stock is MAIA on the New York Stock Exchange

What is the current price of MAIA Biotechnology, Inc. Common Stock?

The current price of MAIA Biotechnology, Inc. Common Stock is 1.240

When was MAIA Biotechnology, Inc. Common Stock last traded?

The last trade of MAIA Biotechnology, Inc. Common Stock was at 04/08/26 08:00 PM ET

What is the market capitalization of MAIA Biotechnology, Inc. Common Stock?

The market capitalization of MAIA Biotechnology, Inc. Common Stock is 45.92M

How many shares of MAIA Biotechnology, Inc. Common Stock are outstanding?

MAIA Biotechnology, Inc. Common Stock has 46M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.